Table 2.
Differentiation study |
Durati on (days) |
Efficien cy (OPC) |
markers | Method (Neuralization) |
Generation of pre- OPC |
Transition from Pre-OPC to OPC |
OPC to oligodendrocyte |
---|---|---|---|---|---|---|---|
Nistor et al., 2005 | 42 | >80% | OLIG1 SOX10 A2B5 NG2, PDGFRα GalC RIP O4 |
EB | FGF EGF RA | EGF | |
Izrael et al., 2007 | >45 | >80% | OLIG1/2 SOX10 NKX2.2 PDGFRα O4 |
EB | EGF RA Noggin | EGF FGF Noggin | Noggin |
Hu et al., 2009 | 112 | >80 % | OLIG2 NKX2.2 PDGFRα O4 |
EB | SHH B27 RA FGF2 | PDGF IGFI NT3 T3 | PDGF IGFI NT3 |
Stacpoole et al., 2013 | 100 | 80% | OLIG2 NKX2.2 NG2 PDGFRα O4 |
EB with low oxygen |
SAG FGF RA (pMN) SAG FGF (forebrain) |
PDGF T3 purmorphamine/SAG RA (pMN) PDGF FGF purmorphamine/SAG T3 (forebrain) |
SAG PDGF NT3 IGFI T3 cAMP |
Wang et al., 2013 | 140 | 70- 90% |
OLIG2 SOX10 NKX2.2 MBP PDGFRα O4 |
EB | RA B27 FGF Purmorphamine |
PDGF IGFI T3 NT3 Purmorphamine |
PDGF IGFI NT3 B27 BDNF |
Douvaras et al., 2014 | 95 | 70% | OLIG2 SOX10 NKX2.2 MBP O4 |
Dual-SMAD inhibition (Monolayer) |
RA SAG | PDGF HGF IGFI NT3 Insulin T3 Biotin cAMP |
Insulin T3 Biotin cAMP AA |
Gorris et al., 2015 | >90 | 80% | OLIG1/2 NKX6.2 NKX2.2 NG2 MBP SOX10 |
EB | PDGF EGF forskolin |
PDGF T3 AA Noggin | T3 AA laminin |
Piao et al., 2015 | 70 | 90% | OLIG2 NKX2.2 SOX10 O1 MBP O4 |
Dual-SMAD and WNT inhibition |
Purmorphamine AA BDNF FGF8 |
PDGF IGFI T3 cAMP | BDNF AA T3 cAMP |
AA: Ascorbic acid RA: retinoic acid EB: Embryoid body